These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 11366558)
1. Lipodystrophy: Glaxo researchers suggest mechanisms, publish data. James JS AIDS Treat News; 1999 Mar; (No 315):1-4. PubMed ID: 11366558 [TBL] [Abstract][Full Text] [Related]
2. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Nolan D; John M; Mallal S Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750 [TBL] [Abstract][Full Text] [Related]
3. Lipodystrophy research coordination needed. James JS AIDS Treat News; 1998 Sep; (303):1-5. PubMed ID: 11365765 [TBL] [Abstract][Full Text] [Related]
4. Changes in body shape and metabolic abnormalities. Res Initiat Treat Action; 1999 Jan; 5(1):18. PubMed ID: 11366225 [TBL] [Abstract][Full Text] [Related]
6. Body composition changes with protease therapy. Berger D Posit Aware; 1998; 9(5):47. PubMed ID: 11365895 [TBL] [Abstract][Full Text] [Related]
7. Lipodrama. Horn T Res Initiat Treat Action; 1999 Dec; 5(5):13-5. PubMed ID: 11366885 [TBL] [Abstract][Full Text] [Related]
8. Are changes in body shape linked to viral load. TreatmentUpdate; 1999 Jun; 11(4):4-5. PubMed ID: 11366791 [TBL] [Abstract][Full Text] [Related]
9. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Tavassoli N; Bagheri H; Sommet A; Delpierre C; Marion-Latard F; Massip P; Aquilina C; Bonnet E; Obadia M; Labau E; Montastruc JL; Bernard J Pharmacotherapy; 2006 Feb; 26(2):154-61. PubMed ID: 16466321 [TBL] [Abstract][Full Text] [Related]
10. On the trail of fugitive fat: the chase turns to NRTIs. Mascolini M J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871 [TBL] [Abstract][Full Text] [Related]
11. Metabolic problems and PIs. Treat Rev; 1997 Nov; (No 26-27):13. PubMed ID: 11364932 [TBL] [Abstract][Full Text] [Related]
12. The new body of AIDS: Crixivan bellies, legs, and humps. McCabe L Newsline People AIDS Coalit N Y; 1998 Sep; ():37-9. PubMed ID: 11367490 [TBL] [Abstract][Full Text] [Related]
13. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy. Kolter DP AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694 [TBL] [Abstract][Full Text] [Related]
15. Acquired immunodeficiency syndrome-related insulin resistance and lipodystrophy: a multifactorial viral and iatrogenic condition. Kino T; Chrousos GP Endocr Pract; 2001; 7(6):480-4. PubMed ID: 11747288 [No Abstract] [Full Text] [Related]
16. Switching from a PI-based to a PI-sparing regimen for management of metabolic or clinical fat redistribution. Moyle G; Baldwin C AIDS Read; 2000 Aug; 10(8):479-85. PubMed ID: 10967808 [TBL] [Abstract][Full Text] [Related]
17. Adverse drug reactions to protease inhibitors. Manchanda T; Schiedel D; Fischer D; Dekaban GA; Rieder MJ Can J Clin Pharmacol; 2002; 9(3):137-46. PubMed ID: 12422251 [TBL] [Abstract][Full Text] [Related]
18. Absence of hypersensitivity to glucocorticoids in antiretroviral-associated lipodystrophy. Martin IP; Breen PA; Weigle DS Obes Res; 2003 Jan; 11(1):21-4. PubMed ID: 12529481 [TBL] [Abstract][Full Text] [Related]